<DOC>
	<DOC>NCT01590641</DOC>
	<brief_summary>Dose cohorts may be dosed with one of up to 4 possible total weekly doses (0.3 mg, 1 mg, 2 mg, 4 mg). Dose escalation or repetition will be governed by pre-specified safety and activity rules. Subjects will be confined on either days 1-3 or days 1-3 and 8-10. Follow-up visits are also required periodically through day 43, and potential viral load follow-up visits at weeks 3 and 6 months post last dose. Study procedures involve blood draws for pharmacokinetic, pharmacodynamic, virologic, and safety assessments</brief_summary>
	<brief_title>A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<criteria>Chronic HBV infection ≥ 6 months HBsAg ≥ 250 IU/mL HBV treatment naïve Absence of extensive bridging fibrosis (Metavir 3 or greater) or cirrhosis Creatinine clearance ≥ 70 mL/min Coinfection with hepatitis C virus (HCV), hepatitis D virus (HDV), or HIV History of Gilberts disease Laboratory parameters not within defined thresholds for leukopenia, neutropenia, anemia, thrombocytopenia, thyroidstimulating hormone (TSH), or other evidence of hepatic decompensation Diagnosis of autoimmune disease, poorly controlled diabetes mellitus, significant psychiatric illness, severe chronic obstructive pulmonary disease(COPD), malignancy, hemoglobinopathy, retinal disease, or patients who are immunosuppressed Evidence of hepatocellular carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Hepatitis</keyword>
	<keyword>Hepatitis B</keyword>
	<keyword>Hepatitis B Virus</keyword>
	<keyword>HBV</keyword>
	<keyword>GS-9620</keyword>
	<keyword>Toll-like receptor (TLR)-7 Agonist</keyword>
</DOC>